Neues zur allergenspezifischen Immuntherapie bei Asthma bronchiale

Translated title of the contribution: New aspects on allergen-specific immunotherapy in bronchial asthma

Matthias Kopp*

*Corresponding author for this work


In the vast majority of children and adolescents with bronchial asthma there is an allergic sensitization against aeroallergens. An allergen-specific immunotherapy (AIT) is principally indicated if a confirmed allergic sensitization is associated with clinical symptoms. Prerequisites are a) the availability of a standardized preparation with proven efficacy and safety in clinical trials and that b) the asthmatic complaints must be controlled. In the daily clinical routine the indications for the treatment option with AIT are often overlooked. The intermittent course of asthmatic symptoms complicate the adherence and compliance of children and their parents to a 3-year long treatment; however, the potential of AIT as a causal treatment option should be discussed for asthma patients, ideally directly after diagnosing allergic asthma.

Translated title of the contributionNew aspects on allergen-specific immunotherapy in bronchial asthma
Original languageGerman
JournalMonatsschrift fur Kinderheilkunde
Issue number11
Pages (from-to)1008-1014
Number of pages7
Publication statusPublished - 01.11.2020

Research Areas and Centers

  • Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)


Dive into the research topics of 'New aspects on allergen-specific immunotherapy in bronchial asthma'. Together they form a unique fingerprint.

Cite this